These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 9375826)

  • 1. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
    Ifudu O; Dawood M; Friedman EA
    Nephron; 1997; 77(3):315-8. PubMed ID: 9375826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist.
    Ifudu O; Dawood M; Homel P; Friedman EA
    Am J Kidney Dis; 1996 Dec; 28(6):841-5. PubMed ID: 8957035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin.
    Kooistra MP; van Es A; Struyvenberg A; Marx JJ
    Br J Haematol; 1991 Dec; 79(4):634-9. PubMed ID: 1772785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia in hemodialysis patients: variables affecting this outcome predictor.
    Madore F; Lowrie EG; Brugnara C; Lew NL; Lazarus JM; Bridges K; Owen WF
    J Am Soc Nephrol; 1997 Dec; 8(12):1921-9. PubMed ID: 9402095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.
    Kalantar-Zadeh K; Höffken B; Wünsch H; Fink H; Kleiner M; Luft FC
    Am J Kidney Dis; 1995 Aug; 26(2):292-9. PubMed ID: 7645533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of AIDS and the response to EPO in uremia.
    Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
    Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
    Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
    Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy.
    Caravaca F; Vagace JM; Aparicio A; Groiss J; Pizarro JL; Alonso N; Garcia MC; Arrobas M; Cubero J; Esparrago J
    Am J Kidney Dis; 1992 Sep; 20(3):249-54. PubMed ID: 1519605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF; Szczech L; Johnson C; Frankenfield D
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in anemia management among US hemodialysis patients.
    Coladonato JA; Frankenfield DL; Reddan DN; Klassen PS; Szczech LA; Johnson CA; Owen WF
    J Am Soc Nephrol; 2002 May; 13(5):1288-95. PubMed ID: 11961017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
    Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
    PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of uremic patients to nandrolone decanoate.
    Doane BD; Fried W; Schwartz F
    Arch Intern Med; 1975 Jul; 135(7):972-5. PubMed ID: 1156056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.